AstraZeneca is resetting the clock to give the Federal Trade Commission more time to review its roughly US$39 billion bid for Alexion Pharmaceuticals, the latter company disclosed Monday, March 15.
In the biggest biopharma deal this year, AstraZeneca has agreed to acquire Alexion Pharmaceuticals, a Boston-based company specializing in rare disease drugs, for US$39 billion.
The deal, which is expected to close sometime between July and September, would have AstraZeneca hand over US$60 in cash and roughly 2.1 American Depositary Shares — each one-half the value of an ordinary AstraZeneca share — for every share of Alexion.
Alexion’s first product, Soliris, which in 2007 became the only FDA-approved treatment for a rare and potentially life-threatening blood disorder called paroxysmal nocturnal hemoglobinuria. For years, Soliris ranked as one of the world’s most expensive medicines, with a list price in the hundreds of thousands of dollars.
Since then, Soliris has been approved to treat three more rare conditions. Alexion has also added four more drugs to its portfolio — one of which, Ultomiris, is meant to offset encroaching challenges to Soliris from generic competition. During the first nine months of this year, Alexion recorded almost US$4.5 billion in net sales, an increase of 24% from the same period in 2019.
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Judge Mehta Questions Both Sides in Landmark Google Antitrust Case
May 2, 2024 by
CPI
FCC Urges Urgent Funding for Removal of Chinese Telecom Equipment from U.S. Networks
May 2, 2024 by
CPI
Former Pioneer CEO Facing Potential Criminal Charges For Colluding With OPEC
May 2, 2024 by
CPI
South Korea’s Antitrust Regulator Greenlights K-Pop Powerhouse Deal
May 2, 2024 by
CPI
Exxon’s Pioneer Purchase Approved, Former CEO Barred from Board
May 2, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI